Strong Or Moderate Cyp3a Inducers + Revumenib Interaction
Majorinteraction on record
Description
Concomitant use should be avoided as it may decrease revumenib systemic exposure and increase M1 metabolite exposure, reducing efficacy or increasing QT prolongation risk.
Mechanism
CYP3A4 inducers increase metabolism of revumenib and increase formation of M1 metabolite
Source: NLP:revumenib